ACADIA Pharmaceuticals Inc (ACAD)
15.08
+0.08
(+0.53%)
USD |
NASDAQ |
May 31, 16:00
15.08
0.00 (0.00%)
After-Hours: 20:00
ACADIA Pharmaceuticals Research and Development Expense (Annual): 351.62M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 351.62M |
| December 31, 2022 | 361.58M |
| December 31, 2021 | 239.42M |
| December 31, 2020 | 319.13M |
| December 31, 2019 | 240.38M |
| December 31, 2018 | 187.16M |
| December 31, 2017 | 149.19M |
| December 31, 2016 | 99.28M |
| December 31, 2015 | 73.87M |
| December 31, 2014 | 60.60M |
| December 31, 2013 | 26.72M |
| December 31, 2012 | 18.79M |
| Date | Value |
|---|---|
| December 31, 2011 | 17.31M |
| December 31, 2010 | 20.58M |
| December 31, 2009 | 41.58M |
| December 31, 2008 | 56.75M |
| December 31, 2007 | 57.94M |
| December 31, 2006 | 49.40M |
| December 31, 2005 | 30.85M |
| December 31, 2004 | 23.45M |
| December 31, 2003 | 16.94M |
| December 31, 2002 | 14.92M |
| December 31, 2001 | 13.09M |
| December 31, 2000 | 9.728M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
239.42M
Minimum
2021
361.58M
Maximum
2022
302.42M
Average
319.13M
Median
2020
Research and Development Expense (Annual) Benchmarks
| Regulus Therapeutics Inc | 21.15M |
| Amylyx Pharmaceuticals Inc | 128.19M |
| Alnylam Pharmaceuticals Inc | 1.004B |
| Cassava Sciences Inc | 89.42M |
| Oragenics Inc | 15.49M |